Drug profile · INN
ergoloid mesylates
GERIMAL
ergoloid mesylates (GERIMAL) is a dopamine receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — ergoloid mesylates
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ergoloid mesylates (GERIMAL) is a dopamine receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine receptor agonist
Primary target: Adrenergic receptor alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ergoloid mesylates?
ergoloid mesylates (GERIMAL) is a dopamine receptor agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ergoloid mesylates?
GERIMAL is a marketed brand name for ergoloid mesylates. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ergoloid mesylates?
ergoloid mesylates has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.